GlobalData, the industry analysis specialist, has released its new report, “Bronchitis Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global bronchitis therapeutics market. The report identifies the key trends shaping and driving the global bronchitis therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global bronchitis sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. The global bronchitis market was valued at $459m in 2009 and is forecast to decline by 3.5% annually for the next seven years to reach $344m in 2017. The typical form of bronchitis is self-limited. The bronchitis market is characterized by many generics and OTC. The NSAIDs (Non Steroidal Anti Inflammatory Drugs), cough suppressants and antipyretics are mere supportive therapies. Antibiotics are highly prescribed to treat atypical form of the disease. The decrease in the market size is attributed to the patent expiration of the branded drugs and the up take of generic drugs
- The scope of the report includes:
- Annualized global Bronchitis therapeutics market revenue data from 2001 to 2009, forecast for eight years to 2017.
- Geographies covered in this report include the United States (US), the United Kingdom (UK), Italy, Spain, Germany, France and Japan.
- Pipeline analysis data providing a split across different phases, mechanisms of action being developed and emerging trends. The key classes of mechanism of action include Topoisomerase II and topoisomerase IV inhibitor, MSC therapy, Oral PDE-IV Inhibitor, and mucomodulator and antioxidant agent.
- Analysis of the current and future market competition in the global bronchitis therapeutic market. The key future market players covered are Osiris Therapeutics, GlaxoSmithKline, Pacific Beach Biosciences, Inc., Pfizer and Edmond Pharma Srl.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include a strategic competitor assessment, a market characterization, the unmet needs and the implications for the bronchitis market.
Reasons to buy
- The report will enhance your decision making capability. It will allow you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
- Develop business strategies by understanding the trends shaping and driving the global bronchitis therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to affect the global bronchitis therapeutics market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What’s the next big thing in the global bronchitis therapeutics market landscape? Identify, understand and capitalize.
Table of Content
1 Table of contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2 Bronchitis Therapeutics: Introduction 4
2.1 Overview 4
2.1.1 Risk Factors 5
2.1.2 Treatment Options 5
2.1.3 Scope of the Report 5
2.2 GlobalData Pipeline Report Guidance 6
3 Bronchitis Thrapeutics: Market Characterization 7
3.1 Bronchitis Market Size 7
3.2 Bronchitis Market Forecast and CAGR 8
3.3 Drivers and Barriers for the Bronchitis Market 10
3.3.1 Drivers for the Bronchitis Market 10
3.3.2 Barriers for the Bronchitis Market 10
3.4 Opportunity and Unmet Need 11
3.5 Key Takeaway 12
4 Global Bronchitis Market: Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3 Product Profile for the Major Marketed Products in the Bronchitis Market 14
4.3.1 Antivirals 14
4.3.2 Antibiotics 15
4.3.3 Bronchodilators and beta2 agonists 16
4.3.4 Analgesics and NSAIDs 18
4.4 Key Takeaway 19
5 Bronchitis Therapeutics: Pipeline Assessment 20
5.1 Overview 20
5.2 Strategic Pipeline Assessment 20
5.3 Product Profiles of the Most Promising Products in the Bronchitis Market 22
5.3.1 Prochymal 22
5.4 Bronchitis Market Clinical Pipeline by Mechanism of Action 23
5.4.1 Bronchitis Disease Phase III Clinical Pipeline 24
5.4.2 Bronchitis Disease Phase II Clinical Pipeline 24
5.5 Key Takeaway 24
6 Global Bronchitis Market: Implications for Future Market Competition 25
7 Bronchitis Therapeutics: Future Players 26
7.1 Introduction 26
7.2 Pfizer Inc. 27
7.2.1 Company Overview 27
7.2.2 Business Description 27
7.2.3 Respiratory Disease Pipeline Product Portfolio 29
7.3 Osiris Therapeutics, Inc. 29
7.3.1 Company Overview 29
7.3.2 Business Description 29
7.3.3 Respiratory Disease Pipeline Product Portfolio 30
7.4 GlaxoSmithKline 30
7.4.1 Company Overview 30
7.4.2 Business Description 31
7.4.3 Respiratory Disease Pipeline Product Portfolio 32
8 Bronchitis Therapeutics: Appendix 33
8.1 Definitions 33
8.2 Acronyms 33
8.3 Research Methodology 33
8.3.1 Coverage 34
8.3.2 Secondary Research 34
8.3.3 Forecasting 34
8.3.4 Primary Research 37
8.3.5 Expert Panel Validation 37
8.4 Contact Us 37
8.5 Disclaimer 37
8.6 Sources 38
List of Table
Table 1: Bronchitis Therapeutics, Global, Revenue ($m), 20012009 8
Table 2: Bronchitis Therapeutics, Global, Market Forecast ($m), 20092017 9
Table 3: Major Marketed Products Comparison for Bronchitis, 2010 19
Table 4: Bronchitis Therapeutics Phase III Clinical Pipeline, 2010 24
Table 5: Bronchitis Therapeutics Phase II Clinical Pipeline, 2010 24
Table 6: Pfizer Inc. Respiratory Disease Pipeline, 2010 29
Table 7: Osiris Therapeutics Inc. Respiratory Disease Pipeline, 2010 30
Table 8: GlaxoSmithKline plc Respiratory Disease Pipeline Products, 2010 32
List of Chart
Figure 1: Bronchitis Therapeutics, Global, Revenue ($m), 20012009 8
Figure 2: Bronchitis Therapeutics, Global, Market Forecast ($m), 20092017 9
Figure 3: Opportunity and Unmet Need in the Bronchitis Therapeutics Market 12
Figure 4: Strategic Competitor Assessment, 2010 13
Figure 5: Technology Trends Analytics Framework of the Bronchitis Therapeutics Pipeline, 2010 20
Figure 6: Technology Trends Analytics Framework of the Bronchitis Therapeutics Pipeline Description, 2010 21
Figure 7: Bronchitis Market Clinical Pipeline by Mechanism of Action, 2010 23
Figure 8: Bronchitis Therapeutics Market Clinical Pipeline by Phase of Development, 2010 23
Figure 9: Implications for Future Market Competition in the Bronchitis Therapeutics Market, 2010 25
Figure 10: Bronchitis Therapeutics Market Pipeline by Company, 2010 26
Figure 11: GlobalData Market Forecasting Model 36
Make an enquiry before buying this Report
Please fill the enquiry form below.